Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$10.93
$4.51
$20.20
$236.61M0.4162,237 shs171,500 shs
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.09
-29.8%
$0.15
$0.09
$1.25
$4.17M-0.244.54 million shs12.28 million shs
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$0.60
$0.67
$0.46
$3.07
$15.91MN/AN/A3,009 shs
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.13
$0.15
$0.03
$0.21
$134.92M-0.161.23 million shs1.12 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
0.00%0.00%0.00%0.00%0.00%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
+3.00%+1.82%-11.38%-4.29%-86.25%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.00%0.00%0.00%0.00%-15.13%
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
-3.14%-10.01%-18.52%-37.68%+297.42%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.2196 of 5 stars
0.05.00.04.62.80.00.0
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
3.00
BuyN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/A

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
$17.26M0.00N/AN/A$4.07 per share0.00
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$0.03 per shareN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
$110K144.65N/AN/A$0.20 per share3.00
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
$34.15M3.95$0.00 per share26.28$0.03 per share4.21

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
-$82.37M-$5.15N/AN/AN/A-230.92%-101.73%-22.35%N/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$1.27N/AN/AN/AN/A-335.11%5/10/2024 (Estimated)
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
-$9.14MN/A0.00N/AN/AN/AN/AN/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
$3.56M$0.0112.64N/A32.87%41.32%26.72%6/29/2024 (Estimated)

Latest ADRO, ATXI, ELTP, and CYAD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/18/2024Q4 2023
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A$0.56+$0.56$0.56N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/AN/AN/AN/AN/A
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/AN/AN/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
N/A
8.91
8.91
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
1.55
1.55
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/AN/AN/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
0.08
1.94
1.19

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
49.93%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
N/A
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%

Insider Ownership

CompanyInsider Ownership
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
5.90%
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
0.94%
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Aduro Biotech, Inc. stock logo
ADRO
Aduro Biotech
15216.21 millionN/AOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
344.26 million43.46 millionNot Optionable
Celyad Oncology SA stock logo
CYAD
Celyad Oncology
9526.52 million26.28 millionNot Optionable
Elite Pharmaceuticals, Inc. stock logo
ELTP
Elite Pharmaceuticals
531.07 billion914.23 millionNot Optionable

ADRO, ATXI, ELTP, and CYAD Headlines

SourceHeadline
Elite Pharmaceuticals, Inc. (ELTP)Elite Pharmaceuticals, Inc. (ELTP)
finance.yahoo.com - April 17 at 7:22 PM
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call TranscriptElite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript
finance.yahoo.com - February 16 at 1:11 PM
Elite Pharmaceuticals Inc Reports Significant Revenue and Operating Profit Growth in Q3 Fiscal 2024Elite Pharmaceuticals Inc Reports Significant Revenue and Operating Profit Growth in Q3 Fiscal 2024
finance.yahoo.com - February 14 at 10:27 PM
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call InformationElite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
finance.yahoo.com - February 14 at 5:26 PM
Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call InformationElite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information
accesswire.com - February 14 at 4:30 PM
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2024 Financial Results on February 15, 2024
finance.yahoo.com - February 8 at 1:11 PM
Elite Pharmaceuticals, Inc.Elite Pharmaceuticals, Inc.
thestreet.com - January 15 at 7:42 AM
Elite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System StimulantElite Pharmaceuticals Files ANDA with US FDA to Market Central Nervous System Stimulant
finance.yahoo.com - December 26 at 7:31 AM
Elite Pharmaceuticals makes first product shipment of generic Adderall XR to PrascoElite Pharmaceuticals makes first product shipment of generic Adderall XR to Prasco
msn.com - December 12 at 8:33 AM
Elite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLCElite Pharmaceuticals Announces First Product Shipment of Generic Adderall XR(R) to Marketing Partner Prasco, LLC
finance.yahoo.com - December 12 at 8:33 AM
Elite Pharmaceuticals Inc ELTPElite Pharmaceuticals Inc ELTP
morningstar.com - November 24 at 11:15 PM
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2024 Earnings Call TranscriptElite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2024 Earnings Call Transcript
finance.yahoo.com - November 20 at 6:07 PM
Elite Pharmaceuticals reports Q3 resultsElite Pharmaceuticals reports Q3 results
msn.com - November 14 at 9:34 PM
Elite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call InformationElite Pharmaceuticals, Inc. Reports Financial Results for Second Quarter of Fiscal Year 2024 ended September 30, 2023 and Provides Conference Call Information
finance.yahoo.com - November 14 at 9:34 PM
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2024 Financial Results on November 15, 2023
finance.yahoo.com - November 10 at 2:54 PM
Elite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic ProductElite Pharmaceuticals Files ANDA with US FDA to Market Opiate Analgesic Product
finance.yahoo.com - September 25 at 10:13 AM
Elite Pharmaceuticals reappoints Carter Ward as CFOElite Pharmaceuticals reappoints Carter Ward as CFO
msn.com - September 7 at 2:36 PM
Elite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial OfficerElite Pharmaceuticals, Inc. Appoints Carter Ward as Chief Financial Officer
finance.yahoo.com - September 7 at 6:54 AM
Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence StudyElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Reports Positive Results from a Pivotal Bioequivalence Study
finanznachrichten.de - August 28 at 11:12 AM
This Weeks Top OTC Nano-Caps (ATVK, ELTP, EBET, ENZC)This Week's Top OTC Nano-Caps (ATVK, ELTP, EBET, ENZC)
benzinga.com - August 28 at 6:12 AM
Discover the Potential: "Top Penny Stocks to Watch Now": SNNC, TIVC, ENZC, ELTP, CLNVDiscover the Potential: "Top Penny Stocks to Watch Now": SNNC, TIVC, ENZC, ELTP, CLNV
benzinga.com - August 22 at 6:15 PM
Elite Pharmaceuticals reports Q1 resultsElite Pharmaceuticals reports Q1 results
seekingalpha.com - August 14 at 8:48 PM
Elite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call InformationElite Pharmaceuticals, Inc. Reports Financial Results for First Quarter of Fiscal Year 2024 ended June 30, 2023 and Provides Conference Call Information
finance.yahoo.com - August 14 at 8:48 PM
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2024 Financial Results on August 15, 2023
finance.yahoo.com - August 9 at 12:05 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Aduro Biotech logo

Aduro Biotech

NASDAQ:ADRO
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering, developing, and commercializing precision medicines for rare, severe chronic kidney diseases. The company was founded in 2019 and is headquartered in Seattle, WA.
Avenue Therapeutics logo

Avenue Therapeutics

NASDAQ:ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Celyad Oncology logo

Celyad Oncology

NASDAQ:CYAD
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Elite Pharmaceuticals logo

Elite Pharmaceuticals

OTCMKTS:ELTP
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.